Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer

References

• Kochanek KD, Xu J, Murphy SL, Miniño AM, Kung H-S. Deaths: preliminary data for 2009. National Vital Statistics Reports 59 No. 4, Division of Vital Statistics, National Center for Health Statistics, MD, USA, 1–51 (2011).
   Google Scholar
• Haber DA, Gray NS, Baselga J. The evolving war on cancer. Cell145, 19–24 (2011).
   PubMed Web of Science ®Google Scholar
• Caskey CT. Using genetic diagnosis to determine individual therapeutic utility. Annu. Rev. Med.61, 1–15 (2010).
   Google Scholar
• Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science294, 858–862 (2001).
   PubMed Web of Science ®Google Scholar
• Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science294, 853–858 (2001).
   PubMed Web of Science ®Google Scholar
• Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science294, 862–864 (2001).
   PubMed Web of Science ®Google Scholar
• Reinhart BJ, Slack FJ, Basson M et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature403, 901–906 (2000).
   PubMed Web of Science ®Google Scholar
• Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell75, 843–854 (1993).
   PubMed Web of Science ®Google Scholar
• Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell75, 855–862 (1993).
   PubMed Web of Science ®Google Scholar
• Ambros V. The functions of animal microRNAs. Nature431, 350–355 (2004).
   PubMed Web of Science ®Google Scholar
• Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat. Rev. Genet.5, 396–400 (2004).
   PubMed Web of Science ®Google Scholar
• Sempere LF, Kauppinen S. Translational implications of microRNAs in clinical diagnostics and therapeutics. In: Handbook of Cell Signaling. Bradshaw RA, Dennis EA (Eds). Academic Press, Oxford, UK, 2965–2981 (2009).
   Google Scholar
• Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell136, 586–591 (2009).
   PubMed Web of Science ®Google Scholar
• Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov.9, 775–789 (2010).
   PubMed Web of Science ®Google Scholar
• De SE, Ferretti E, Gulino A. MicroRNAs as biomarkers for CNS cancer and other disorders. Brain Res.1338, 100–111 (2010).
   Google Scholar
• Saba R, Schratt GM. MicroRNAs in neuronal development, function and dysfunction. Brain Res.1338, 3–13 (2010).
   PubMedGoogle Scholar
• Ketting RF. MicroRNA biogenesis and function: an overview. Adv. Exp. Med. Biol.700, 1–14 (2011).
   PubMed Web of Science ®Google Scholar
• Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet.11, 597–610 (2010).
   PubMed Web of Science ®Google Scholar
• Bentwich I, Avniel A, Karov Y et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat. Genet.37, 766–770 (2005).
   PubMed Web of Science ®Google Scholar
• Lim LP, Lau NC, Garrett-Engele P et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature433, 769–773 (2005).
   PubMed Web of Science ®Google Scholar
• Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature455, 58–63 (2008).
   PubMed Web of Science ®Google Scholar
• Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature455, 64–71 (2008).
   PubMed Web of Science ®Google Scholar
• Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res.39, D152–D157 (2011).
   PubMed Web of Science ®Google Scholar
• Ferracin M, Veronese A, Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert. Rev. Mol. Diagn.10(3), 297–308 (2010).
   PubMed Web of Science ®Google Scholar
• Elmen J, Lindow M, Silahtaroglu A et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res.36, 1153–1162 (2008).
   PubMed Web of Science ®Google Scholar
• Elmen J, Lindow M, Schutz S et al. LNA-mediated microRNA silencing in non-human primates. Nature452, 896–899 (2008).
   PubMed Web of Science ®Google Scholar
• Trang P, Wiggins JF, Daige CL et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther.19(6), 1116–1122 (2011).
   PubMed Web of Science ®Google Scholar
• Wiggins JF, Ruffino L, Kelnar K et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res.70, 5923–5930 (2010).
   PubMed Web of Science ®Google Scholar
• Trang P, Medina PP, Wiggins JF et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene29, 1580–1587 (2010).
   PubMed Web of Science ®Google Scholar
• Ma L, Reinhardt F, Pan E et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol.28, 341–347 (2010).
   PubMed Web of Science ®Google Scholar
• Szafranska-Schwarzbach AE, Adai AT, Lee LS, Conwell DL, Andruss BF. Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma. Expert. Rev. Mol. Diagn.11, 249–257 (2011).
   PubMed Web of Science ®Google Scholar
• Matos LL, Trufelli DC, de Matos MG, da Silva Pinhal MA. Immunohistochemistry as an important tool in biomarkers detection and clinical practice. Biomark. Insights5, 9–20 (2010).
   PubMedGoogle Scholar
• Brennan DJ, O’Connor DP, Rexhepaj E, Ponten F, Gallagher WM. Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat. Rev. Cancer10, 605–617 (2010).
   PubMed Web of Science ®Google Scholar
• Tholouli E, Sweeney E, Barrow E, Clay V, Hoyland JA, Byers RJ. Quantum dots light up pathology. J. Pathol.216, 275–285 (2008).
   Google Scholar
• Al-Janabi S, Huisman A, Van Diest PJ. Digital pathology: current status and future perspectives. Histopathology DOI: 10.1111/j.1365-2559.2011.03814.x (2011) (Epub ahead of print).
   Google Scholar
• Chen X, Zheng B, Liu H. Optical and digital microscopic imaging techniques and applications in pathology. Anal. Cell Pathol.34, 5–18 (2011).
   Web of Science ®Google Scholar
• Schwanhausser B, Busse D, Li N et al. Global quantification of mammalian gene expression control. Nature473, 337–342 (2011).
   PubMed Web of Science ®Google Scholar
• Kauppinen S, Vester B, Wengel J. Locked nucleic acid: high-affinity targeting of complementary RNA for RNomics. Handb. Exp. Pharmacol.405–422 (2006).
   PubMedGoogle Scholar
• Nelson PT, Baldwin DA, Kloosterman WP, Kauppinen S, Plasterk RH, Mourelatos Z. RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. RNA12, 187–191 (2006).
   PubMed Web of Science ®Google Scholar
• Sempere LF, Christensen M, Silahtaroglu A et al. Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res.67, 11612–11620 (2007).
   PubMed Web of Science ®Google Scholar
• Yamamichi N, Shimomura R, Inada K et al. Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin. Cancer Res.15, 4009–4016 (2009).
   PubMed Web of Science ®Google Scholar
• Liu X, Sempere LF, Ouyang H et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J. Clin. Invest.120, 1298–1309 (2010).
   PubMed Web of Science ®Google Scholar
• Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J. Gastrointest. Surg.12, 2171–2176 (2008).
   PubMed Web of Science ®Google Scholar
• Habbe N, Koorstra JB, Mendell JT et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol. Ther.8, 340–346 (2009).
   PubMed Web of Science ®Google Scholar
• Preis M, Gardner TB, Gordon SR et al. microRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin. Cancer Res.17, 5812–5821 (2011).
   PubMed Web of Science ®Google Scholar
• Schneider M, Andersen DC, Silahtaroglu A et al. Cell-specific detection of microRNA expression during cardiomyogenesis by combined in situ hybridization and immunohistochemistry. J. Mol. Histol.42, 289–299 (2011).
   PubMedGoogle Scholar
• Donnem T, Eklo K, Berg T et al. Prognostic impact of miR-155 in non-small cell lung cancer evaluated by in situ hybridization. J. Transl. Med.9, 6 (2011).
   PubMed Web of Science ®Google Scholar
• Gupta A, Mo YY. Detection of microRNAs in cultured cells and paraffin-embedded tissue specimens by in situ hybridization. Methods Mol. Biol.676, 73–83 (2011).
   PubMedGoogle Scholar
• Nelson PT, Dimayuga J, Wilfred BR. MicroRNA in situ hybridization in the human entorhinal and transentorhinal cortex. Front. Hum. Neurosci.4, 7 (2010).
   Google Scholar
• Schepeler T, Reinert JT, Ostenfeld MS et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res.68, 6416–6424 (2008).
   PubMed Web of Science ®Google Scholar
• Nielsen BS, Jorgensen S, Fog JU et al. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin. Exp. Metastasis28, 27–38 (2011).
   PubMed Web of Science ®Google Scholar
• Sempere LF, Preis M, Yezefski T et al. Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered microRNA expression in solid tumors. Clin. Cancer Res.16, 4246–4255 (2010).
   PubMed Web of Science ®Google Scholar
• Nelson PT, Wilfred BR. In situ hybridization is a necessary experimental complement to microRNA (miRNA) expression profiling in the human brain. Neurosci. Lett.466, 69–72 (2009).
   PubMed Web of Science ®Google Scholar
• Speel EJ, Hopman AH, Komminoth P. Tyramide signal amplification for DNA and mRNA in situ hybridization. Methods Mol. Biol.326, 33–60 (2006).
   Google Scholar
• Sempere LF, Korc M. Fully-automated multi-color co-detection of microRNA and protein biomarkers on formalin-fixed paraffin-embedded specimens of solid tumors. Presented at: 36th Annual National Society for Histotechnology Symposium/Convention. Seattle, WA, USA, 24–29 September 2010.
   Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60, 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature406, 747–752 (2000).
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA98, 10869–10874 (2001).
   PubMed Web of Science ®Google Scholar
• Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur. J. Cancer40, 2667–2675 (2004).
   PubMed Web of Science ®Google Scholar
• Sims AH, Ong KR, Clarke RB, Howell A. High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic? Breast Cancer Res.8, 214 (2006).
   PubMedGoogle Scholar
• Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA295, 2492–2502 (2006).
   PubMed Web of Science ®Google Scholar
• Ross JS. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome. Adv. Anat. Pathol.16, 204–215 (2009).
   PubMedGoogle Scholar
• Overdevest JB, Theodorescu D, Lee JK. Utilizing the molecular gateway: the path to personalized cancer management. Clin. Chem.55, 684–697 (2009).
   PubMed Web of Science ®Google Scholar
• Cheang MC, Voduc D, Bajdik C et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res.14, 1368–1376 (2008).
   PubMed Web of Science ®Google Scholar
• Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl. Cancer Inst.101, 736–750 (2009).
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med.351, 2817–2826 (2004).
   PubMed Web of Science ®Google Scholar
• Weigelt B, Hu Z, He X et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res.65, 9155–9158 (2005).
   PubMed Web of Science ®Google Scholar
• Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol.27, 1160–1167 (2009).
   PubMed Web of Science ®Google Scholar
• DeNardo DG, Brennan DJ, Rexhepaj E et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Dis. DOI: 10.1158/2159-8274.CD-10-0028 (2011) (Epub ahead of print).
   Google Scholar
• Planche A, Bacac M, Provero P et al. Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer. PLoS ONE6, e18640 (2011).
   PubMed Web of Science ®Google Scholar
• Marchini C, Montani M, Konstantinidou G et al. Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies. PLoS ONE5, e14131 (2010).
   Google Scholar
• Sharma M, Beck AH, Webster JA et al. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ. Breast Cancer Res. Treat.123, 397–404 (2010).
   PubMedGoogle Scholar
• Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res.11, R7 (2009).
   PubMed Web of Science ®Google Scholar
• Farmer P, Bonnefoi H, Anderle P et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med.15, 68–74 (2009).
   PubMed Web of Science ®Google Scholar
• Finak G, Bertos N, Pepin F et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med.14, 518–527 (2008).
   PubMed Web of Science ®Google Scholar
• Iorio MV, Ferracin M, Liu CG et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res.65, 7065–7070 (2005).
   PubMed Web of Science ®Google Scholar
• Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA103, 2257–2261 (2006).
   PubMed Web of Science ®Google Scholar
• Andorfer CA, Necela BM, Thompson EA, Perez EA. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol. Med.17, 313–319 (2011).
   PubMed Web of Science ®Google Scholar
• Le QJ, Caldas C. Micro-RNAs and breast cancer. Mol. Oncol.4, 230–241 (2010).
   Google Scholar
• Rothe F, Ignatiadis M, Chaboteaux C et al. Global MicroRNA expression profiling identifies miR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS ONE6, e20980 (2011).
   PubMed Web of Science ®Google Scholar
• Janssen EA, Slewa A, Gudlaugsson E et al. Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Mod. Pathol.23, 1567–1576 (2010).
   PubMed Web of Science ®Google Scholar
• Lowery AJ, Miller N, Devaney A et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res.11, R27 (2009).
   PubMed Web of Science ®Google Scholar
• Blenkiron C, Goldstein LD, Thorne NP et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumour subtype. Genome Biol.8, R214 (2007).
   PubMed Web of Science ®Google Scholar
• Mattie MD, Benz CC, Bowers J et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer5, 24 (2006).
   PubMed Web of Science ®Google Scholar
• Castellano L, Giamas G, Jacob J et al. The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response. Proc. Natl Acad. Sci. USA106, 15732–15737 (2009).
   PubMed Web of Science ®Google Scholar
• Yoshimoto N, Toyama T, Takahashi S et al. Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer. Breast Cancer Res. Treat.130(1), 331–339(2011).
   PubMed Web of Science ®Google Scholar
• Fu SW, Chen L, Man YG. miRNA biomarkers in breast cancer detection and management. J. Cancer2, 116–122 (2011).
   PubMed Web of Science ®Google Scholar
• Foekens JA, Sieuwerts AM, Smid M et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc. Natl Acad. Sci. USA105, 13021–13026 (2008).
   PubMed Web of Science ®Google Scholar
• Camps C, Buffa FM, Colella S et al. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin. Cancer Res.14, 1340–1348 (2008).
   PubMed Web of Science ®Google Scholar
• Buffa FM, Camps C, Winchester L et al. microRNA associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res.71(17), 5635–5645 (2011).
   PubMed Web of Science ®Google Scholar
• Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle10, 507–517 (2011).
   PubMed Web of Science ®Google Scholar
• Crosby ME, Kulshreshtha R, Ivan M, Glazer PM. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res.69, 1221–1229 (2009).
   PubMed Web of Science ®Google Scholar
• Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat. Rev. Clin. Oncol.7, 153–162 (2010).
   PubMed Web of Science ®Google Scholar
• Pino MS, Chung DC. Microsatellite instability in the management of colorectal cancer. Expert Rev. Gastroenterol. Hepatol.5, 385–399 (2011).
   PubMed Web of Science ®Google Scholar
• Fearon ER. Molecular genetics of colorectal cancer. Annu. Rev. Pathol.6, 479–507 (2011).
   PubMed Web of Science ®Google Scholar
• Mutch MG. Molecular profiling and risk stratification of adenocarcinoma of the colon. J. Surg. Oncol.96, 693–703 (2007).
   Google Scholar
• Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J. Clin. Oncol.29, 17–24 (2011).
   PubMed Web of Science ®Google Scholar
• Luo X, Burwinkel B, Tao S, Brenner H. MicroRNA signatures: novel biomarker for colorectal cancer? Cancer Epidemiol. Biomarkers Prev.20, 1272–1286 (2011).
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhang P, Yang J, Liu Z, Yang Z, Qin H. Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. Int. J. Cancer DOI: 10.1002/ijc.26232 (2011) (Epub ahead of print).
   Google Scholar
• Lanza G, Ferracin M, Gafa R et al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol. Cancer6, 54 (2007).
   PubMed Web of Science ®Google Scholar
• Kulda V, Pesta M, Topolcan O et al. Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer Genet. Cytogenet.200, 154–160 (2010).
   PubMed Web of Science ®Google Scholar
• Schetter AJ, Leung SY, Sohn JJ et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA299, 425–436 (2008).
   PubMed Web of Science ®Google Scholar
• Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology79, 313–320 (2010).
   PubMed Web of Science ®Google Scholar
• Yen LC, Uen YH, Wu DC et al. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann. Surg.251, 254–260 (2010).
   PubMed Web of Science ®Google Scholar
• Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin. Ther.32, 437–453 (2010).
   PubMed Web of Science ®Google Scholar
• Blanke CD, Goldberg RM, Grothey A et al. KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. Oncologist16(8), 1061–1068 (2011).
   PubMedGoogle Scholar
• Solmi R, Lauriola M, Francesconi M et al. Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines. BMC Cancer8, 227 (2008).
   PubMedGoogle Scholar
• Ragusa M, Majorana A, Statello L et al. Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol. Cancer Ther.9, 3396–3409 (2010).
   PubMed Web of Science ®Google Scholar
• Zhang W, Winder T, Ning Y et al. A let-7 microRNA-binding site polymorphism in 3´-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann. Oncol.22, 104–109 (2011).
   PubMed Web of Science ®Google Scholar
• Graziano F, Canestrari E, Loupakis F et al. Genetic modulation of the let-7 microRNA binding to KRAS 3´-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab–irinotecan. Pharmacogenomics J.10, 458–464 (2010).
   PubMed Web of Science ®Google Scholar
• Wistuba II, Gazdar AF. Lung cancer preneoplasia. Annu. Rev. Pathol.1, 331–348 (2006).
   PubMed Web of Science ®Google Scholar
• Bhattacharjee A, Richards WG, Staunton J et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA98, 13790–13795 (2001).
   PubMed Web of Science ®Google Scholar
• Garber ME, Troyanskaya OG, Schluens K et al. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl Acad. Sci. USA98, 13784–13789 (2001).
   PubMed Web of Science ®Google Scholar
• Yamagata N, Shyr Y, Yanagisawa K et al. A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin. Cancer Res.9, 4695–4704 (2003).
   PubMedGoogle Scholar
• Ring BZ, Seitz RS, Beck RA et al. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod. Pathol.22, 1032–1043 (2009).
   Google Scholar
• Beer DG, Kardia SL, Huang CC et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med.8, 816–824 (2002).
   PubMed Web of Science ®Google Scholar
• Powell CA, Spira A, Derti A et al. Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am. J. Respir. Cell Mol. Biol.29, 157–162 (2003).
   PubMed Web of Science ®Google Scholar
• Spira A, Beane JE, Shah V et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat. Med.13, 361–366 (2007).
   PubMed Web of Science ®Google Scholar
• Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J. Natl. Cancer Inst.102, 464–474 (2010).
   PubMed Web of Science ®Google Scholar
• Lacroix L, Commo F, Soria JC. Gene expression profiling of non-small-cell lung cancer. Expert Rev. Mol. Diagn.8, 167–178 (2008).
   Web of Science ®Google Scholar
• Roepman P, Jassem J, Smit EF et al. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin. Cancer Res.15, 284–290 (2009).
   PubMed Web of Science ®Google Scholar
• Du L, Pertsemlidis A. MicroRNAs and lung cancer: tumors and 22-mers. Cancer Metastasis Rev.29, 109–122 (2010).
   PubMed Web of Science ®Google Scholar
• Lin PY, Yu SL, Yang PC. MicroRNA in lung cancer. Br. J. Cancer103, 1144–1148 (2010).
   PubMed Web of Science ®Google Scholar
• Yendamuri S, Kratzke R. MicroRNA biomarkers in lung cancer: MiRacle or quagMiRe? Transl. Res.157, 209–215 (2011).
   PubMedGoogle Scholar
• Landi MT, Zhao Y, Rotunno M et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin. Cancer Res.16, 430–441 (2010).
   PubMed Web of Science ®Google Scholar
• Lebanony D, Benjamin H, Gilad S et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J. Clin. Oncol.27, 2030–2037 (2009).
   PubMed Web of Science ®Google Scholar
• Fassina A, Cappellesso R, Fassan M. Classification of non-small cell lung carcinoma in trans-thoracic needle specimens using microRNA expression profiling. Chest DOI: 10.1378/chest.11-0708 (2011) (Epub ahead of print).
   Google Scholar
• Del V, V, Cantaloni C, Cucino A et al. miR-205 expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am. J. Surg. Pathol.35, 268–275 (2011).
   PubMedGoogle Scholar
• Xing L, Todd NW, Yu L, Fang H, Jiang F. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod. Pathol.23, 1157–1164 (2010).
   PubMed Web of Science ®Google Scholar
• Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP, Westra WH. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin. Cancer Res.16, 610–619 (2010).
   PubMed Web of Science ®Google Scholar
• Yanaihara N, Caplen N, Bowman E et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell.9, 189–198 (2006).
   PubMed Web of Science ®Google Scholar
• Saito M, Schetter AJ, Mollerup S et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin. Cancer Res.17, 1875–1882 (2011).
   PubMed Web of Science ®Google Scholar
• Voortman J, Goto A, Mendiboure J et al. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res.70, 8288–8298 (2010).
   PubMed Web of Science ®Google Scholar
• Fruh M. The search for improved systemic therapy of non-small cell lung cancer – what are today’s options? Lung Cancer72, 265–270 (2011).
   Google Scholar
• Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J. Clin. Oncol.28, 4769–4777 (2010).
   PubMed Web of Science ®Google Scholar
• Read ML, Spice R, Parker AL, Mir S, Logan A. 12th Annual Congress of the European Society of Gene Therapy. Expert Opin. Biol. Ther.5, 137–141 (2005).
   PubMed Web of Science ®Google Scholar
• Chin LJ, Ratner E, Leng S et al. A SNP in a let-7 microRNA complementary site in the KRAS 3´ untranslated region increases non-small cell lung cancer risk. Cancer Res.68, 8535–8540 (2008).
   PubMed Web of Science ®Google Scholar
• Nelson HH, Christensen BC, Plaza SL, Wiencke JK, Marsit CJ, Kelsey KT. KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. Lung Cancer69, 51–53 (2010).
   Google Scholar
• Weiss GJ, Bemis LT, Nakajima E et al. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann. Oncol.19, 1053–1059 (2008).
   PubMed Web of Science ®Google Scholar
• Rai K, Takigawa N, Ito S et al. Liposomal delivery of microRNA-7-expressing plasmid overcomes epidermal growth factor receptor-tyrosine kinase inhibitor-resistance in lung cancer cells. Mol. Cancer Ther.10(9), 1720–1727 (2011).
   PubMed Web of Science ®Google Scholar
• Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J. Biol. Chem.284, 5731–5741 (2009).
   PubMed Web of Science ®Google Scholar
• Subramanian J, Simon R. What should physicians look for in evaluating prognostic gene-expression signatures? Nat. Rev. Clin. Oncol.7, 327–334 (2010).
   PubMed Web of Science ®Google Scholar
• Xu JZ, Wong CW. Hunting for robust gene signature from cancer profiling data: sources of variability, different interpretations, and recent methodological developments. Cancer Lett.296, 9–16 (2010).
   PubMedGoogle Scholar
• Hu Z, Fan C, Oh DS et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics7, 96 (2006).
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature435, 834–838 (2005).
   PubMed Web of Science ®Google Scholar
• Ferracin M, Pedriali M, Veronese A et al. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J. Pathol.225(1), 43–45 (2011).
   PubMed Web of Science ®Google Scholar
• Varadhachary GR, Spector Y, Abbruzzese JL et al. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin. Cancer Res.17, 4063–4070 (2011).
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer11, 426–437 (2011).
   PubMed Web of Science ®Google Scholar
• Mostert B, Sieuwerts AM, Martens JW, Sleijfer S. Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert Rev. Mol. Diagn.11, 259–275 (2011).
   PubMed Web of Science ®Google Scholar
• Brase JC, Wuttig D, Kuner R, Sultmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol. Cancer9, 306 (2010).
   PubMed Web of Science ®Google Scholar
• Scholer N, Langer C, Dohner H, Buske C, Kuchenbauer F. Serum microRNAs as a novel class of biomarkers: a comprehensive review of the literature. Exp. Hematol.38, 1126–1130 (2010).
   PubMed Web of Science ®Google Scholar
• Hipp J, Cheng J, Hanson JC et al. SIVQ-aided laser capture microdissection: a tool for high-throughput expression profiling. J. Pathol. Inform.2, 19 (2011).
   Google Scholar
• Hanson JC, Tangrea MA, Kim S et al. Expression microdissection adapted to commercial laser dissection instruments. Nat. Protoc.6, 457–467 (2011).
   Google Scholar
• Kim MS, Kim T, Kong SY et al. Breast cancer diagnosis using a microfluidic multiplexed immunohistochemistry platform. PLoS. ONE5, e10441 (2010).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Gonzalez FG, Sieuwerts AM, Smid M et al. MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res. Treat.127, 43–51 (2011).
   PubMed Web of Science ®Google Scholar
• Ota D, Mimori K, Yokobori T et al. Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients. Int. J. Oncol.38, 955–962 (2011).
   PubMed Web of Science ®Google Scholar
• Yu SL, Chen HY, Chang GC et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell13, 48–57 (2008).
   PubMed Web of Science ®Google Scholar
• Raponi M, Dossey L, Jatkoe T et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res.69, 5776–5783 (2009).
   PubMed Web of Science ®Google Scholar
• Gong C, Yao Y, Wang Y et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J. Biol. Chem.286, 19127–19137 (2011).
   PubMed Web of Science ®Google Scholar
• Qian B, Katsaros D, Lu L et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Res. Treat.117, 131–140 (2009).
   PubMed Web of Science ®Google Scholar
• Yan LX, Huang XF, Shao Q et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA14, 2348–2360 (2008).
   PubMed Web of Science ®Google Scholar
• Drebber U, Lay M, Wedemeyer I et al. Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. Int. J. Oncol.39, 409–415 (2011).
   PubMed Web of Science ®Google Scholar
• Diaz R, Silva J, Garcia JM et al. Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer47, 794–802 (2008).
   PubMed Web of Science ®Google Scholar
• Nishida N, Yokobori T, Mimori K et al. MicroRNA miR-125b is a prognostic marker in human colorectal cancer. Int. J. Oncol.38, 1437–1443 (2011).
   PubMed Web of Science ®Google Scholar
• Takamizawa J, Konishi H, Yanagisawa K et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res.64, 3753–3756 (2004).
   PubMed Web of Science ®Google Scholar
• Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin. Chem.54, 1696–1704 (2008).
   PubMed Web of Science ®Google Scholar
• Gao W, Shen H, Liu L, Xu J, Xu J, Shu Y. miR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J. Cancer Res. Clin. Oncol.137, 557–566 (2011).
   PubMed Web of Science ®Google Scholar
• Gallardo E, Navarro A, Vinolas N et al.miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis30, 1903–1909 (2009).
   PubMed Web of Science ®Google Scholar